The purpose of this study is to evaluate the long-term safety and efficacy of GENOSS PCB in patients with long femoropopliteal lesions who underwent percutaneous transluminal angioplasty using GENOSS PCB.
Subject was ≥19 years of age.
Subject had target limb Rutherford classification 2, 3, 4 or 5.
Subjects with a stenosis of 70% or greater in the femoropopliteal artery.
Subjects with a stenotic or occlusive lesion measuring ≥150 mm in total length. (Multiple adjacent lesions separated by less than 3 cm from angiographically healthy segments are treated as a single lesion.)
Subjects was allergic to paclitaxel.
Subjects with contraindications or hypersensitivity to antiplatelet therapy.
Subject had life expectancy of less than 2 years.
Those who have undergone vascular surgery on the target lesion within the past 6 weeks.